This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (58)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Study of 211 Patients

Morie A. Gertz, MD; Robert A. Kyle, MD; W. Michael O'Fallon, PhD

Arch Intern Med. 1992;152(11):2245-2250.

Abstract
. Background.
The study assessed dialysis support in pa tients with primary systemic amyloidosis without associated multiple myeloma in whom renal insufficiency developed.

Methods.
The study group consisted of 211 patients with biopsy-proved primary systemic amyloidosis examined at the Mayo Clinic, Rochester, Minn. No patient was lost to follow-up.

Results.
Thirty-seven (18%) of the patients received di alysis therapy. Of those presenting with renal amyloid, one third received dialysis. The median time from diagnosis to initiation of dialysis was 13.8 months. The median survival for patients from the start of dialysis was 8.2 months. There was no survival difference between hemodialysis (n=27) and peritoneal dialysis (n=10). The most important predictors of which patients would ultimately require dialysis were the 24-hour urinary protein loss and serum creatinine values at the time amyloidosis was diagnosed. None of the patients seen at diagnosis with a normal serum creatinine value and proteinuria of less than 2 g/d required dialysis during follow up. Of the 37 patients who received dialysis, 31 died, and 21 of the 31 died as a result of extrarenal progression of their systemic amyloidosis. Fifteen of the 31 deaths were a result of cardiac amyloidosis. All long-term survivors had normal echocardiograms without evidence of amyloid.

Conclusion.
Eighteen percent of patients with primary amyloidosis undergo dialysis. The 24-hour urinary protein loss and creatinine values are helpful in predicting which patients eventually will require dialysis. The median survival for patients starting dialysis is less than 1 year. Patients whose two-dimensional echocardiograms are normal are most likely to derive long-term benefit from dialysis.

(Arch Intern Med. 1992;152:2245-2250)

Author Affiliations
From the Dysproteinemia Clinic (Drs Gertz and Kyle) and the Section of Biostatistics (Dr O'Fallon), Mayo Clinic and Mayo Foundation, Roch ester, Minn.

Footnotes
Accepted for publication April 10, 1992.

Presented in part at the 33rd Annual Meeting of the American Society of Hematology, Denver, Colo, December 9, 1991.

Reprint requests to Dysproteinemia Clinic, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (Dr Gertz).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney
Gertz et al.
Nephrol Dial Transplant 2009;24:3132-3137.
ABSTRACT | FULL TEXT  

Renal involvement in AL amyloidosis: the facts, the promise and the hope
Ronco and Aucouturier
Nephrol Dial Transplant 2009;24:2967-2969.
FULL TEXT  

Clinical and histological responses of renal amyloidosis to high-dose melphalan supported by autologous stem cell transplantation
Sanada et al.
Nephrol Dial Transplant 2008;23:747-750.
FULL TEXT  

Amyloidosis-Associated Kidney Disease
Dember
J. Am. Soc. Nephrol. 2006;17:3458-3471.
ABSTRACT | FULL TEXT  

Multiple Myeloma
Korbet and Schwartz
J. Am. Soc. Nephrol. 2006;17:2533-2545.
FULL TEXT  

Primary (AL) Amyloidosis in Plasma Cell Disorders
Muller et al.
The Oncologist 2006;11:824-830.
ABSTRACT | FULL TEXT  

Myeloma - new approaches to combined nephrological-haematological management
Haubitz and Peest
Nephrol Dial Transplant 2006;21:582-590.
FULL TEXT  

No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement
Zeier et al.
Nephrol Dial Transplant 2003;18:2644-2647.
ABSTRACT | FULL TEXT  

Recovery of acute renal failure and nephrotic syndrome following autologous stem cell transplantation for primary (AL) amyloidosis
Snanoudj et al.
Nephrol Dial Transplant 2003;18:2175-2177.
FULL TEXT  

Efficacy of haemodiafiltration treatment with PEPA dialysis membranes in plasma free light chain removal in a patient with primary amyloidosis
Machiguchi et al.
Nephrol Dial Transplant 2002;17:1689-1691.
FULL TEXT  

Effect of Dose-Intensive Intravenous Melphalan and Autologous Blood Stem-Cell Transplantation on AL Amyloidosis-Associated Renal Disease
Dember et al.
ANN INTERN MED 2001;134:746-753.
ABSTRACT | FULL TEXT  

AA amyloidosis in Takayasu's arteritis—long-term survival on maintenance haemodialysis
Wada et al.
Nephrol Dial Transplant 1999;14:2478-2481.
FULL TEXT